Skip to main content

Advanced/Metastatic Solid Malignancies clinical trials at UC Irvine
1 research study open to eligible people

  • IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

    open to eligible people ages 18 years and up

    The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies. Patients will be recruited for 2 cohorts: • Cohort 1: Advanced/metastatic cancers with TMB>10 mutations per megabase (mut/Mb). This enrollment of this cohort has been stopped per sponsor's communication with the sites. For patients who have already enrolled in this cohort, treatment and monitoring will be conducted as stipulated by the protocol. The patients will remain on study until disease progression or intolerable toxicity, death, withdrawal of consent, or end of study, whichever occurs first. Cohort 2: Advanced/metastatic endometrial cancer (N=40)

    Orange, California and other locations

Last updated: